Brilinta
Flu Vaccines May Protect the Heart Too »
"Oct. 28, 2012 -- Flu vaccines may do more than guard against infection. New research hints that the vaccine, which is recommended for all adults, may also help the heart.
Two new studies presented at the 2012 Canadian Cardiovascular C"...
Brilinta
BRILINTA®
(ticagrelor) Tablets for Oral Administration
WARNING
BLEEDING RISK
- BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS).
- Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage.
- Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery (See WARNINGS AND PRECAUTIONS).
- Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA.
- If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events ( See WARNINGS AND PRECAUTIONS).
WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
- Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day (See WARNINGS AND PRECAUTIONS and Clinical Studies).
DRUG DESCRIPTION
BRILINTA contains ticagrelor, a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor. Chemically it is (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5- (propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. The empirical formula of ticagrelor is C23H28F2N6O4S and its molecular weight is 522.57. The chemical structure of ticagrelor is:
 |
Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 μg/mL at room temperature.
BRILINTA tablets for oral administration contain 90 mg of ticagrelor and the following ingredients: mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, talc, polyethylene glycol 400, and ferric oxide yellow.
Last reviewed on RxList: 4/15/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Brilinta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Heart Health
Get the latest treatment options.
Updated & New
